| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
N/A |
| Shares
Out: |
61,150,000 |
| Market
Cap: |
6.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$113.49 - $145.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
12,000 |
12,000 |
12,000 |
| Total Buy Value |
$0 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
1 |
| Total Shares Sold |
8,704 |
9,538 |
24,727 |
196,382 |
| Total Sell Value |
$986,699 |
$1,086,171 |
$3,194,336 |
$28,520,846 |
| Total People Sold |
2 |
4 |
12 |
19 |
| Total Sell Transactions |
3 |
5 |
20 |
73 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cox Russell J. |
EVP & COO |
• – – |
2017-02-27 |
4 |
D |
$136.97 |
$343,384 |
D/D |
(2,507) |
44,588 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2017-02-27 |
4 |
D |
$136.97 |
$1,406,956 |
D/D |
(10,272) |
279,891 |
|
- |
|
| Wilson Karen J |
SVP, Finance & PAO |
• – – |
2017-02-27 |
4 |
D |
$136.97 |
$128,067 |
D/D |
(935) |
15,825 |
|
- |
|
| Young Matthew P. |
EVP & CFO |
• – – |
2017-02-27 |
4 |
D |
$136.97 |
$273,118 |
D/D |
(1,994) |
31,913 |
|
- |
|
| Hooper Suzanne Sawochka |
EVP & General Counsel |
• – – |
2017-02-27 |
4 |
D |
$136.97 |
$343,932 |
D/D |
(2,511) |
69,236 |
|
- |
|
| Mcgill Iain |
SVP, Europe & Rest of World |
• – – |
2017-02-27 |
4 |
D |
$136.97 |
$235,725 |
D/D |
(1,721) |
16,701 |
|
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2017-02-15 |
4 |
AS |
$134.55 |
$26,910 |
D/D |
(200) |
16,486 |
|
- |
|
| Cox Russell J. |
EVP & COO |
• – – |
2017-01-18 |
4 |
AS |
$125.00 |
$515,000 |
D/D |
(4,000) |
47,095 |
|
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2017-01-17 |
4 |
AS |
$115.93 |
$23,186 |
D/D |
(200) |
16,686 |
|
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2016-12-15 |
4 |
AS |
$103.09 |
$20,618 |
D/D |
(200) |
16,886 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2016-12-02 |
4 |
AS |
$101.80 |
$68,919 |
D/D |
(677) |
1,365 |
|
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2016-11-15 |
4 |
AS |
$112.19 |
$22,438 |
D/D |
(200) |
16,925 |
|
- |
|
| Okeefe Kenneth W |
Director |
– • – |
2016-11-14 |
4 |
B |
$112.45 |
$56,224 |
I/I |
500 |
2,000 |
2.1 |
- |
|
| Okeefe Kenneth W |
Director |
– • – |
2016-11-11 |
4 |
B |
$114.30 |
$171,465 |
I/I |
1,500 |
1,500 |
2.1 |
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2016-10-17 |
4 |
AS |
$118.16 |
$23,632 |
D/D |
(200) |
17,125 |
|
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2016-09-19 |
4 |
AS |
$126.17 |
$25,234 |
D/D |
(200) |
17,325 |
|
- |
|
| Mulligan Seamus |
Director |
– • – |
2016-08-25 |
4 |
AS |
$126.65 |
$3,588,787 |
D/D |
(27,968) |
1,048,008 |
|
- |
|
| Treacy Paul |
SVP, Technical Operations |
• – – |
2016-08-16 |
4 |
S |
$137.46 |
$177,609 |
D/D |
(1,292) |
13,870 |
|
- |
|
| Berns Paul L |
Director |
– • – |
2016-08-15 |
4 |
S |
$136.45 |
$86,373 |
D/D |
(633) |
5,234 |
|
- |
|
| Winningham Rick E |
Director |
– • – |
2016-08-15 |
4 |
S |
$136.45 |
$86,373 |
D/D |
(633) |
15,391 |
|
- |
|
| Sohn Catherine A. |
Director |
– • – |
2016-08-15 |
4 |
S |
$136.45 |
$86,373 |
D/D |
(633) |
6,116 |
|
- |
|
| Riedel Norbert G |
Director |
– • – |
2016-08-15 |
4 |
S |
$136.45 |
$86,373 |
D/D |
(633) |
4,953 |
|
- |
|
| Mcsharry Heather Ann |
Director |
– • – |
2016-08-15 |
4 |
S |
$136.45 |
$93,468 |
D/D |
(685) |
6,076 |
|
- |
|
| Enright Patrick G |
Director |
– • – |
2016-08-15 |
4 |
S |
$136.45 |
$86,373 |
D/D |
(633) |
2,042 |
|
- |
|
| Miller Michael Patrick |
SVP, US Commercial |
• – – |
2016-08-15 |
4 |
AS |
$136.45 |
$13,645 |
D/D |
(100) |
17,525 |
|
- |
|
881 Records found
|
|
Page 24 of 36 |
|
|
0.37 (0.34%) 
